Osteoarthritis of Knee Clinical Trial
Official title:
Adaptative, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled, Clinical Trial, on the Efficacy and Tolerability of Different Escalating Doses of Intra-articular Clodronate in Patients With Painful Knee Osteoarthritis
The goal of this clinical trial is to to clarify which is the best dose of administration, to select a dose and to confirm the therapeutic efficacy of clodronate in patients with painful knee osteoarthritis (OA). The clinical trial will be divided in two parts. The main questions it aims to answer are: - in Phase II, to assess the safety and tolerability of different escalating doses of intra articular (IA) clodronate - in Phase II, to set a defined therapeutic dose (DTD) to be used in Phase III - in Phase III, to assess the safety and tolerability of different escalating doses of IA clodronate to confirm and extensively evaluate the therapeutic efficacy and safety of the clodronate DTD in patients with knee OA
Status | Recruiting |
Enrollment | 296 |
Est. completion date | October 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 75 Years |
Eligibility | Inclusion Criteria: - Female and male patients aged 50 up to 75 years at ICF signature. - Diagnosis of knee OA according to the American College of Rheumatology, confirmed by Rx during the screening (a Rx performed in the last 3 months before Baseline is accepted). - Kellgren-Lawrence radiographic score between 2 and 3 degrees in the tibiofemoral joint. - Symptomatic knee OA (pain) since at least 6 months with a knee pain (VAS) ranging between 40 and 80 mm at Screening visit (the figure should be confirmed at Baseline). - Female patients of childbearing potential must have a negative pregnancy test before each treat-ment and during the Visit 5 - Week 4 and they must use adequate methods of contraception throughout the course of the study. - A signed ICF by the patient after exhaustive study discussion with the investigators. Exclusion Criteria: - BMI > 35 kg/m² (Class II obesity). - Joint instability due to other reasons than knee OA, such as f.i. algo dystrophic syndrome, either partial or complete rupture of internal / externals ligaments, kneecap instability, etc. - Otherwise located lower limb pain, such as hip pain. - Other musculoskeletal disorders related to the target knee. - Any treatment with IA drugs in the last 3 months before Day 0 - Baseline (including any formulation of corticosteroids or hyaluronic acid injections). - Corticosteroid use by any systemic route, and hyaluronic acid injection or intraarticular corticosteroids for any other joint in the previous month will not be permitted. - Any treatment with systemic non-steroidal anti-inflammatory drugs (NSAIDs) in the week before enrolment, or any steroid anti-inflammatory drugs and chondroprotective drugs in the thirty (30) days before month before Baseline. - Any treatment with systemic bisphosphonates in the last twelve (12) months before Baseline. - Any treatment with Glucosamine or Chondroitin sulfate, Diacerein and Matrix metalloproteinase (MMP) inhibitors in the 4 weeks before Baseline. - Any treatment with Denosumab in the twelve (12) months before Baseline. - Any treatment with Paracetamol in the twelve (12) hours before Baseline. - Any knee surgery in the past or knee arthroplasty. - Any diagnostic or surgical arthroscopy of the knee in the six (6) months before Baseline. - Any jaw osteonecrosis in the last twenty-four (24) months before Baseline or at a risk of jaw osteonecrosis. - Any known hypersensitivity to the drug in the study to its excipients or other bisphosphonates, and any hypersensitivity to Paracetamol (rescue drug). - Any participation in a clinical study in which the last administration of the investigational medicinal product was within two (2) weeks before consenting to study participation (i.e.signing ICF). - Inadequate organ function defined by the following laboratory parameters: 1. Absolute Neutrophil Count (ANC) < 1500/µl. 2. Hemoglobin (Hb) < 9 g/dl (< Hb 5.6 mmol/L) 3. Platelet Count < 100.000/µl 4. Serum Creatinine > 1.5 x Upper limit normal (ULN) or estimated Glomerular Filtration Rate (eGFR) < 60 mL/min (as per Cockroft-Gault formula). 5. Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST)> 1.5 x Upper limit normal(ULN). 6. Serum Total Bilirubin > 1.5 x Upper limit normal (ULN). - Pregnant or breastfeeding women, or women planning to become pregnant during the study. - Any positive or suspected history of alcoholism or drug use. - Clinically significant (i.e.) gastrointestinal, renal, hepatic, pulmonary, cardiovascular or neurological disease that could interfere with the outcome of the study or the patient's ability to comply with study requirements. - Patients unwilling or unable to comply with the protocol. |
Country | Name | City | State |
---|---|---|---|
Italy | Centro Riabilitativo Polifunzionale Teresio Borsalino | Alessandria | |
Italy | IRCCS Istituti Clinici Maugeri | Castel Goffredo | Mantova |
Italy | Ospedale San Pellegrino | Castiglione delle Stiviere | Mantova |
Italy | IRCCS Ospedale Policlinico San Martino | Genova | |
Italy | Azienda Ospedaliera Universitaria San Luigi Gonzaga | Orbassano | Torino |
Italy | Ospedale Israelitico | Roma | |
Italy | Ospedale San Pietro | Rome | |
Italy | Ospedale San Paolo | Savona | |
Italy | Azienda Ospedaliero Universitaria Senese | Siena | |
Italy | Ospedale Policlinico "G.B. Rossi" Borgo Roma | Verona | |
Italy | Ospedale Civile Servizio di Riabilitazione Funzionale | Volta Mantovana | Mantova |
Lead Sponsor | Collaborator |
---|---|
SPA Società Prodotti Antibiotici S.p.A. | Pharmaceutical Development and Services |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | SAE Reporting | Recording of Serious adverse event (SAE) and abnormal laboratory or any clinical signs of intolerance across the patients' visits. | At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15 | |
Other | AE Reporting | Recording of adverse event (AE) | At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15 | |
Other | Clinical signs of intolerance Recording | Recording of any clinical signs of intolerance across the patients' visits | At Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15 | |
Primary | Efficacy: VAS Reduction | A clodronate dose will be considered as effective when a = 10 mm reduction in the Visual Analogue Scale (VAS) of knee pain will be observed at Week 7 vs. Placebo | Week 7 | |
Secondary | VAS mean changes | Mean changes in the Visual Analogue Scale (VAS) of knee pain observed at each other visit than Week 7 vs. Placebo and vs Baseline. | At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 11, 15 | |
Secondary | VAS mean changes observed 120 minutes after IA | Mean changes in the Visual Analogue Scale (VAS) of knee pain observed 120 minutes after IA injection at Baseline, Weeks 1, 2 and 3 vs predose assessment | At Baseline and at Weeks 1, 2 and 3 | |
Secondary | Lequesne Algofunctional Index mean changes | Mean changes in the Lequesne Algofunctional Index at each visit vs Placebo and vs Baseline. | At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15 | |
Secondary | WOMAC mean changes | Mean changes in the (WOMAC) Western Scale Ontario MacMaster Index at each visit vs Placebo and vs Baseline. | At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15 | |
Secondary | Range of motion mean changes | Mean changes in the Range of Motion at each visit vs Placebo and vs Baseline. | At Screening, at Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15 | |
Secondary | Paracetamol consumption | Use of rescue drug consumption (paracetamol) across the patients visits | At Baseline, at Weeks 1, 2, 3, 4, 5, 7, 11, 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03274713 -
Efficacy of Electro-acupuncture Versus Manual Acupuncture on Knee Osteoarthritis
|
N/A | |
Completed |
NCT04535596 -
Blood Flow Restriction Exercises and Conservative Exercises in Knee Osteoarthritis
|
N/A | |
Completed |
NCT03918291 -
Whole-body Vibration Training on Functional Performance of the Elderly With Knee Osteoarthritis
|
N/A | |
Completed |
NCT01453738 -
Allogeneic Mesenchymal Stem Cells in Osteoarthritis
|
Phase 2 | |
Active, not recruiting |
NCT01027819 -
Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT01186211 -
Feasibility of Outpatient Total Knee Arthroplasty
|
||
Active, not recruiting |
NCT00261066 -
Outcome Following Orthopaedic Surgery
|
||
Completed |
NCT03484910 -
Biofeedback With Cycling Exercise in OA Knee Patients
|
N/A | |
Recruiting |
NCT03884374 -
Pain Relief for OsteoArthritis Through Combined Treatment (PROACT)
|
N/A | |
Completed |
NCT03492320 -
Progression of Health Related Quality of Life of Patients Waiting for Total Knee Arthroplasty
|
||
Completed |
NCT01449552 -
Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT
|
N/A | |
Completed |
NCT06254976 -
Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis
|
N/A | |
Completed |
NCT03428893 -
Mobile Technology to Support Physical Therapy Exercise
|
N/A | |
Completed |
NCT05081921 -
Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases
|
Phase 1/Phase 2 | |
Completed |
NCT02850068 -
Geniculate Artery Embolization for the Treatment of Knee Pain
|
N/A | |
Active, not recruiting |
NCT03110172 -
Short-term Efficacy of Antidepressant in Patients Underwent TKA
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT02623660 -
Microcurrent Stimulation Reduces Post-Operative Swelling and Healing Time Following Knee Replacement Surgery
|
N/A | |
Completed |
NCT02579174 -
Total Knee Replacement Component Alignment Using Manual Versus Custom Instrumentation
|
N/A | |
Completed |
NCT00790985 -
Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee
|
N/A | |
Recruiting |
NCT02722811 -
Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis
|
N/A |